Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2001 2
2002 4
2003 5
2005 1
2006 1
2007 2
2008 1
2009 6
2010 8
2011 12
2012 15
2013 14
2014 14
2015 15
2016 12
2017 24
2018 16
2019 17
2020 15
2021 11
2022 21
2023 18
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Results by year

Filters applied: . Clear all
Page 1
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ, Hyrich KL, Pope JE, de Souza S, Stamm TA, Takeuchi T, Verschueren P, Winthrop KL, Balsa A, Bathon JM, Buch MH, Burmester GR, Buttgereit F, Cardiel MH, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder AA, El Aoufy K, Finckh A, Fonseca JE, Gottenberg JE, Haavardsholm EA, Iagnocco A, Lauper K, Li Z, McInnes IB, Mysler EF, Nash P, Poor G, Ristic GG, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland TPM, Westhovens R, van der Heijde D. Smolen JS, et al. Among authors: den broeder aa. Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. Epub 2022 Nov 10. Ann Rheum Dis. 2023. PMID: 36357155
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D. Smolen JS, et al. Among authors: den broeder aa. Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Epub 2020 Jan 22. Ann Rheum Dis. 2020. PMID: 31969328 Free article.
Preface.
den Broeder AA, Woodworth TG. den Broeder AA, et al. Best Pract Res Clin Rheumatol. 2015 Aug-Dec;29(4-5):525-6. doi: 10.1016/j.berh.2015.09.008. Epub 2015 Nov 28. Best Pract Res Clin Rheumatol. 2015. PMID: 26697763 No abstract available.
Authors' reply.
Mahler E, Cuperus N, Bijlsma J, Vliet Vlieland T, van den Hoogen F, den Broeder AA, van den Ende CH. Mahler E, et al. Among authors: den broeder aa. Scand J Rheumatol. 2017 Mar;46(2):169-170. doi: 10.1080/03009742.2016.1238961. Epub 2016 Dec 13. Scand J Rheumatol. 2017. PMID: 27957869 No abstract available.
Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study.
van der Togt CJT, Van den Bemt B, Aletaha D, Alten R, Chatzidionysiou K, Galloway J, Isaac J, Mulleman D, Verschueren P, Vulto AG, Welsing PMJ, Verhoef L, den Broeder AA. van der Togt CJT, et al. Among authors: den broeder aa. RMD Open. 2023 Mar;9(1):e002898. doi: 10.1136/rmdopen-2022-002898. RMD Open. 2023. PMID: 36863753 Free PMC article. Review.
[Polymyalgia rheumatica: new developments and challenges].
Marsman DE, den Broeder AA, Boers N, van der Maas A. Marsman DE, et al. Among authors: den broeder aa. Ned Tijdschr Geneeskd. 2017;161:D1647. Ned Tijdschr Geneeskd. 2017. PMID: 29192568 Review. Dutch.
Urate-lowering therapy following a treat-to-target continuation strategy compared to a treat-to-avoid-symptoms discontinuation strategy in gout patients in remission (GO TEST Finale): study protocol of a multicentre pragmatic randomized superiority trial.
Peeters IR, den Broeder AA, Taylor WJ, den Broeder N, Flendrie M, van Herwaarden N. Peeters IR, et al. Among authors: den broeder aa. Trials. 2023 Apr 19;24(1):282. doi: 10.1186/s13063-023-07242-y. Trials. 2023. PMID: 37072799 Free PMC article.
206 results